Asensus Surgical

Asensus Surgical Equity

Delisted

The The Equity of Asensus Surgical (ASXC) as of Oct 22, 2026 is 33.41 M USD. In the previous year, The Equity was 99.65 M USD — a change of -66.47% (lower).

Equity

33.41 MUSD

YoY

-66.47%

Last updated:

In 2023, Asensus Surgical's equity was 33.41 M USD, a -66.47% increase from the 99.65 M USD equity in the previous year.

The Asensus Surgical Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2016
117.87 M USD
Jan 1, 2017
178.85 M USD
Jan 1, 2018
168.52 M USD
Jan 1, 2019
55.54 M USD
Jan 1, 2020
61.57 M USD
Jan 1, 2021
169.25 M USD
Jan 1, 2022
99.65 M USD
Jan 1, 2023
33.41 M USD
The Asensus Surgical Equity history
YEAREquityYoY
33.41 MUSD-66.47%
99.65 MUSD-41.12%
169.25 MUSD+174.89%
61.57 MUSD+10.87%
55.54 MUSD-67.05%
168.52 MUSD-5.77%
178.85 MUSD+51.73%
117.87 MUSD-33.51%
177.28 MUSD+45.56%
121.79 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Asensus Surgical Stock analysis

What does Asensus Surgical do? Asensus Surgical Inc is a medical technology company based in Research Triangle Park, North Carolina, USA. It was founded in 1995 by Joe Mussallem, who still serves as President and CEO today. Formerly known as "TransEnterix," the company changed its name to Asensus Surgical Inc in 2021 to reflect its commitment to advanced, data-driven surgery. Asensus Surgical Inc aims to revolutionize the way surgical procedures are performed by utilizing robotic technology and offering a wide range of products and services. The company's business model is based on transferring skills typically held by surgeons to robots, with a focus on precision in surgeries. Through the use of machine learning and computer vision, Asensus Surgical Inc allows surgeons to monitor their own movements in real-time on robotic arms in the operating room, leading to significantly more precise work. The company's main division is the Senhance® Surgical System platform. The system consists of three components: the artificial intelligence technology of the Intelligent Surgical Units (ISU), touchscreen consoles, and a further sterilization cabinet. During surgical procedures, the Intelligent Surgical Units process real-time data, enabling improved decision-making during the operation. The touchscreen consoles serve as the user interface, allowing surgeons to monitor and control the operation in real-time on a screen. The sterilization cabinet ensures that the system is sterilized between procedures. In addition to the Senhance® Surgical System platform, Asensus Surgical Inc also offers other innovative products such as disposable instruments. This includes "3-mm instruments," special miniature instruments that can be used through very small incisions in the patient's body. These minimize scarring and enable faster recovery. Another product offered by Asensus Surgical Inc is the AI Camera Assistant, which is based on artificial intelligence (AI). This is a computer software that supports surgeons by analyzing real-time images and enabling monitoring and analysis during the procedure. Combined with the Senhance® Surgical System, the AI Camera Assistant allows for more precise and safer work. Asensus Surgical Inc has achieved several significant milestones in its history. One of these milestones is the FDA approval of the Senhance® Surgical System platform in 2017. Furthermore, in 2020, the company entered into an agreement with Johnson & Johnson to advance the marketing of products. Overall, Asensus Surgical Inc is an emerging company in the highly innovative field of robotics in surgery. With its advanced products and focus on precise, safe, and straightforward surgery, the company will continue to play an important role in the healthcare industry, saving and improving lives. Asensus Surgical is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Asensus Surgical's Equity

Asensus Surgical's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Asensus Surgical's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Asensus Surgical's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Asensus Surgical's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Asensus Surgical’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Asensus Surgical stock

The Equity of Asensus Surgical is 33.41 M USD in 2023.

The Equity of Asensus Surgical changed from 99.65 M USD to 33.41 M USD, representing a -66.47% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Asensus Surgical since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Asensus Surgical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Asensus Surgical

All Key Metrics — Asensus Surgical